Osteogenic sarcoma and cisplatin chemotherapy in dogs: 16 cases (1986-1989).
Sixteen dogs, given adjuvant cisplatin chemotherapy after amputation for osteogenic sarcoma of the appendicular skeleton, had a median survival time of 413 days. Ten dogs (62%) were alive 1 year after amputation. Dogs were given cisplatin at a dosage of 50 mg/m2 of body surface every 4 weeks for a total of 6 cisplatin treatments, or until metastatic disease was detected. Cisplatin chemotherapy was well-tolerated by most dogs, with only 1 dog developing serious gastrointestinal toxicosis, requiring hospitalization. Results of this study support other investigators' findings that when a cisplatin chemotherapy-based protocol is administered, survival times after amputation can be prolonged for dogs with osteogenic sarcoma.
Kraegel
S A
SA
Department of Surgery, School of Veterinary Medicine, University of California, Davis 95616.
Madewell
B R
BR
Simonson
E
E
Gregory
C R
CR
D000671:Amputation, Surgical / Q000662:veterinary*; D000818:Animals; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004283:Dog Diseases / Q000188:drug therapy* / Q000601:surgery; D004285:Dogs; D005260:Female; D008297:Male; D012516:Osteosarcoma / Q000188:drug therapy / Q000601:surgery / Q000662:veterinary*; D012189:Retrospective Studies
D002945:Cisplatin